By Stephen Nakrosis
SC II Acquisition, a blank-check company affiliated with Nukkleus, filed for a $150 million initial public offering.
The company said its sponsor, SC Capital II Sponsor, is an indirect subsidiary of Nukkleus which is a financial technology company whose shares trade on the Nasdaq under the symbol NUKK.
SC II said Menachem Shalom, its chief executive and a director, has been CEO of Nukkleus since September 2024. Shalom is also CEO and a director of special purpose acquisition company Kochav Defense Acquisition, which completed its IPO in May.
Asaf Yarkoni, SC II's chief financial officer, has been CFO of Kamari Pharma since 2021, and is also CFO of Kochav Defense Acquisition.
SC II said it hasn't selected a business combination target, and may pursue an acquisition opportunity in any business, industry, sector or geographical location.
The company applied to list its units on The Nasdaq Global Market under the symbol SCIIU.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 16, 2025 18:14 ET (22:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.